Academic Alliance in Dermatology

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

The Dermatology Digest

SEPTEMBER 9, 2024

Obagi Introduces Two New Elastiderm Products Obagi Medical is launching Elastiderm Lift Up & Sculpt Facial Moisturizer and Elastiderm Advanced Filler Concentrate. The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S.

Portfolios 36

Portfolios Dermatology Injections Innovations 36

The Dermatology Digest

AUGUST 20, 2024

There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population. The adverse events were consistent with the known safety profile of Otezla in adult patients. sPGA response for Otezla versus 10.8% for placebo (95% CI: 12.2%, 32.4%. For more information, visit Otezla.com.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

JUNE 18, 2024

Permanent makeup can help restore confidence in people with certain skin and hair conditions, according to a new article in the Journal of the American Academy of Dermatology. In South Carolina, permanent makeup is regulated by the state’s medical board.

Permanent Makeup 36

Permanent Makeup Makeup Sanitation and Sterilization Dermatology 36

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Clinic Office 74

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Safety 77

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Safety 74

Safety Dermatology Clinic Therapy 74

The Dermatology Digest

AUGUST 13, 2024

” The Crnic Institute study team is now overseeing a second trial testing the safety and efficacy of the JAK inhibitor relative to other medicines for treating the condition known as Down Syndrome Regression Disorder , and a third trial focused on children with Down syndrome is expected to start recruitment in late 2024. .”

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 2, 2024

New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. What’s New in ‘Natural’ Sunscreens?

Ingredients 74

Ingredients Safety Innovations Dermatology 74

The Dermatology Digest

JUNE 12, 2024

The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. The post Tox Update: Evolus Launches Nuceiva in Spain appeared first on The Dermatology Digest. Evolus, Inc. is rolling out Nuceiva (botulinum toxin type A) across Spain.

Safety 36

Safety Branding Facials Clinic 36

The Dermatology Digest

DECEMBER 20, 2023

Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. Head of the SAB, Is a Professor of Dermatology with Penn State Health Hershey Medical Center, and Penn State College of Medicine. is a Professor of Dermatology and Director of Dermatologic Surgery at the University of Minnesota.

Dermatology 36

Dermatology Surgery Eczema Office 36

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

AUGUST 14, 2024

Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study. The Company also plans to submit the final Phase 2 data for presentation at future medical meetings.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

North Dallas Dermatology Associates

NOVEMBER 1, 2023

After all, who wouldn’t want to be in the capable hands of a medical professional? While practitioners in medical spas and salons may offer discounted rates, there is often a concerning lack of specialized training. This added layer of safety provides peace of mind to patients.

Office 36

Office Safety Medical Training 36

US Dermatologt Partners

JUNE 1, 2024

1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. A study involving 245 patients showed significant improvements at 16 weeks, confirming its efficacy and safety in younger populations.6

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

FEBRUARY 5, 2024

We are honored to be recognized for the 2024 People’s Choice Award by Octane’s esteemed judges, entrepreneurs and experts in dermatology and plastic surgery,” says Dina El-Sherif, MBA, founder and CEO of Trufacial, in a news release (Pictured above).

Dermatology 36

Dermatology Pharmaceutical Technology Sales 36

The Dermatology Digest

MAY 14, 2024

The American Skin Association’s (ASA) SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the upcoming 2024 Society for Investigative Dermatology (SID) Annual Meeting in Dallas, TX. ” ASA Chairman, Howard P.

Sun Protection 36

Sun Protection Partnerships Education Safety 36

The Dermatology Digest

MARCH 5, 2024

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. The post And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines appeared first on The Dermatology Digest. and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% The post Phase 2 Data: Extra-strength Jeuveau Smooths Frown Lines for Up to 6 Months appeared first on The Dermatology Digest. of adverse events were rated as mild and no serious adverse events were identified.

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Dermatology Injections 36

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

JULY 10, 2024

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Treatment with Zoryve foam significantly increased the odds of achieving a meaningful improvement in quality of life at Weeks 2, 4, and 8, compared to vehicle as measured by the Dermatology Life Quality Index (DLQI), the study showed.

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

AUGUST 13, 2024

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

JUNE 20, 2024

The FDA approval was supported by results from the two pivotal Phase 3 ‘CARDIGAN’ studies which evaluated the efficacy and safety of Sofdra versus vehicle and enrolled 701 patients with primary axillary hyperhidrosis. The post FDA Approves Sofpironium Gel for Primary Axillary Hyperhidrosis appeared first on The Dermatology Digest.

Safety 36

Safety Dermatology Clinic Medical 36

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. We are pleased to be able to share these individual response data with the wider dermatology community, and develop a better understanding about the broad range of clinical responses for roflumilast cream in this condition.”

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

MAY 31, 2024

The Company states that STS-01 “builds on a mechanism with a well established safety profile in dermatology, and existing evidence of efficacy in this indication through targeting key relevant cytokines. ” Complete study results are expected to be presented at a future medical meeting.

Hospital 36

Hospital Safety Dermatology Clinic 36

The Dermatology Digest

JANUARY 30, 2024

The Pediatric Dermatology Research Alliance (PeDRA) has awarded nearly $240K to support pediatric dermatology research across four competitive grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

MARCH 9, 2024

The new research included integrated data from Measure Up 1 and Measure Up 2, two phase 3 studies looking at the efficacy and safety profile of upadacitinib 15mg and 30mg in adolescents and adults with moderate-to-severe AD.

Dermatitis 36

Dermatitis Safety Dermatology Medical 36

The Dermatology Digest

JANUARY 24, 2024

It is a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules. No specific treatment-emergent safety concerns were identified for delgocitinib cream, and the overall safety profile was consistent with what was observed in DELTA 1, 2 and 3.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

FEBRUARY 7, 2024

IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe plaque psoriasis (PsO) and underpins the inflammatory response in PsO and other dermatological and gastroenterological IL-23-mediated diseases. JNJ-2113 is the first and only investigational targeted oral peptide inhibitor designed to block the IL-23 receptor.

Safety 36

Safety Clinic Office Dermatology 36

US Dermatologt Partners

MARCH 27, 2024

Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. Thus began research into the potential medicinal uses of red light therapy for a variety of health conditions, which is already widely medically accepted in its use as photodynamic therapy.

Therapy 41

Therapy Treatments Dermatology Safety 41

The Dermatology Digest

FEBRUARY 27, 2024

. “The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36